Home > Gastroenterology > HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By
Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA
Conference
ASCO GI 2022
Trial
Phase 3, HIMALAYA
Tremelimumab plus durvalumab improved the overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib. Also, durvalumab monotherapy was non-inferior to sorafenib. Durvalumab monotherapy and the combination with tremelimumab had manageable safety profiles and may represent new first-line treatment options for this population [1]. “First-line options for patients with uHCC have been limited, with sorafenib and lenvatinib being the main options,” Prof. Ghassan Abou-Alfa (Memorial Sloan Kettering Center, NY, USA) said. “These agents have been associated with a median OS of approximately 1 year and quality-of-life reducing toxicity.” Recently, atezolizumab and bevacizumab outperformed sorafenib [2]. Also, tremelimumab, a CTLA-4 inhibitor, plus durvalumab, a PD-L1 inhibitor, showed promising activity in this population in a phase 2...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on